Orphan medicinal products

Orphan medicinal products are intended for the analysis, prevention or treatment of dangerous or very serious conditions that affect no more than 5 in 10,000 people in the European Union. Patients suffering from rare diseases deserve the same quality of treatment as other patients within the European Union. Given the small numbers of patients affected by rare diseases, the pharmaceutical industry has been unwilling in the past to invest in the research and development of medicinal products to treat them. The EU introduced new legislation in 2000 with the aim of providing incentives for the development of medicines for rare diseases (so-called orphan medicinal products).

  • Orphan designation
  • Medicines for rare diseases

Related Conference of Orphan medicinal products

August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
September 19-20, 2025

18th World Drug Delivery Summit

Paris, France
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 24-25, 2025

5th World Congress on Rare Diseases & Orphan Drugs

Aix-en-Provence, France
November 13-14, 2025

21st International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Paris, France
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, Aland Islands
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands

Orphan medicinal products Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in